SAMe has been widely studied for the treatment of osteoarthritis. There is evidence that SAMe may reduce the pain of osteoarthritis and may be well tolerated. Results suggest that SAMe may be more effective than placebo and as effective as anti-inflammatory drugs.
Early evidence suggests that SAMe may benefit adults with ADHD. Higher-quality studies are needed before conclusions can be made.
Bile flow improvement
Some evidence suggests that SAMe may treat symptoms linked to bile flow problems. However, information is still limited. SAMe has been studied during feeding through the vein for the treatment of bile flow problems. Higher-quality research is needed in this area.
Bile flow improvement (pregnancy)
Firm conclusions are lacking on the use of SAMe for bile flow problems during pregnancy. Early research suggests that SAMe may lack benefit over placebo in treating symptoms of the condition. In the available studies, SAMe appears to be well tolerated in mothers or newborns. Information on the use of SAMe before the third trimester is lacking.
SAMe has been widely studied for use in depression and bipolar disorder. However, high-quality studies are lacking. Some available evidence suggests that SAMe may be more effective than placebo. Most trials comparing SAMe to antidepressants are short-term only (less than three weeks). It is known that antidepressants require at least 4-6 weeks to show full effectiveness. Trials lasting for six weeks suggest a lack of significant effect of SAMe. High-quality research that compares SAMe to other antidepressants and lasts at least six weeks is needed. Firm conclusions are lacking at this time.
Fibromyalgia (chronic muscle pain)
Fibromyalgia is known to cause chronic pain and depressive symptoms. SAMe has been studied for the relief of these symptoms. Evidence is mixed with regard to possible benefits of SAMe. More research is needed before firm conclusions can be made.
Liver disease (general)
Early evidence suggests that SAMe may benefit people who have liver disease. The use of nutrition supplements, such as SAMe, has been studied for liver disease. High-quality clinical trials are needed before conclusions can be made.
Nervous system disorders (genetic)
Early research suggests that SAMe may improve cognitive problems associated with various genetic disorders. SAMe has also been studied for nervous system disorders related to genetic disorders, such as Lesch-Nyhan syndrome (a condition that affects the breakdown of purines, natural compounds in the body). More high-quality research is needed to form conclusions.
Early research suggests that SAMe may treat some symptoms of schizophrenia. These include aggression, quality of life, and depression. However, SAMe may cause irritability. More research is needed in this area.
Sepsis (severe response to infection)
Early human research suggests that a combination treatment involving SAMe may protect the liver in people with sepsis. More studies are needed to determine the effects of SAMe alone.
Sexual function / libido / erectile dysfunction
Early human research suggests that SAMe may benefit sexual function. Further research is needed in order to make a firm conclusion
Supplementing with SAMe has been suggested as a way to help smokers quit. Early study has found a lack of effectiveness. Higher-quality research is needed to make conclusions.